2023-08-012024-07-312024-07-31false13535358AKOMA THERAPY LTD2025-03-2686900falseiso4217:GBPxbrli:pure135353582023-08-01135353582024-07-31135353582023-08-012024-07-31135353582022-08-01135353582023-07-31135353582022-08-012023-07-3113535358bus:SmallEntities2023-08-012024-07-3113535358bus:AuditExempt-NoAccountantsReport2023-08-012024-07-3113535358bus:AbridgedAccounts2023-08-012024-07-3113535358bus:PrivateLimitedCompanyLtd2023-08-012024-07-3113535358core:WithinOneYear2024-07-3113535358core:AfterOneYear2024-07-3113535358core:WithinOneYear2023-07-3113535358core:AfterOneYear2023-07-3113535358core:ShareCapital2024-07-3113535358core:SharePremium2024-07-3113535358core:RevaluationReserve2024-07-3113535358core:OtherReservesSubtotal2024-07-3113535358core:RetainedEarningsAccumulatedLosses2024-07-3113535358core:ShareCapital2023-07-3113535358core:SharePremium2023-07-3113535358core:RevaluationReserve2023-07-3113535358core:OtherReservesSubtotal2023-07-3113535358core:RetainedEarningsAccumulatedLosses2023-07-3113535358core:LandBuildings2024-07-3113535358core:PlantMachinery2024-07-3113535358core:Vehicles2024-07-3113535358core:FurnitureFittings2024-07-3113535358core:OfficeEquipment2024-07-3113535358core:NetGoodwill2024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-07-3113535358core:ListedExchangeTraded2024-07-3113535358core:UnlistedNon-exchangeTraded2024-07-3113535358core:LandBuildings2023-07-3113535358core:PlantMachinery2023-07-3113535358core:Vehicles2023-07-3113535358core:FurnitureFittings2023-07-3113535358core:OfficeEquipment2023-07-3113535358core:NetGoodwill2023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-07-3113535358core:ListedExchangeTraded2023-07-3113535358core:UnlistedNon-exchangeTraded2023-07-3113535358core:LandBuildings2023-08-012024-07-3113535358core:PlantMachinery2023-08-012024-07-3113535358core:Vehicles2023-08-012024-07-3113535358core:FurnitureFittings2023-08-012024-07-3113535358core:OfficeEquipment2023-08-012024-07-3113535358core:NetGoodwill2023-08-012024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3113535358core:ListedExchangeTraded2023-08-012024-07-3113535358core:UnlistedNon-exchangeTraded2023-08-012024-07-3113535358core:MoreThanFiveYears2023-08-012024-07-3113535358core:Non-currentFinancialInstruments2024-07-3113535358core:Non-currentFinancialInstruments2023-07-3113535358dpl:CostSales2023-08-012024-07-3113535358dpl:DistributionCosts2023-08-012024-07-3113535358core:LandBuildings2023-08-012024-07-3113535358core:PlantMachinery2023-08-012024-07-3113535358core:Vehicles2023-08-012024-07-3113535358core:FurnitureFittings2023-08-012024-07-3113535358core:OfficeEquipment2023-08-012024-07-3113535358dpl:AdministrativeExpenses2023-08-012024-07-3113535358core:NetGoodwill2023-08-012024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3113535358dpl:GroupUndertakings2023-08-012024-07-3113535358dpl:ParticipatingInterests2023-08-012024-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2023-08-012024-07-3113535358core:ListedExchangeTraded2023-08-012024-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-08-012024-07-3113535358core:UnlistedNon-exchangeTraded2023-08-012024-07-3113535358dpl:CostSales2022-08-012023-07-3113535358dpl:DistributionCosts2022-08-012023-07-3113535358core:LandBuildings2022-08-012023-07-3113535358core:PlantMachinery2022-08-012023-07-3113535358core:Vehicles2022-08-012023-07-3113535358core:FurnitureFittings2022-08-012023-07-3113535358core:OfficeEquipment2022-08-012023-07-3113535358dpl:AdministrativeExpenses2022-08-012023-07-3113535358core:NetGoodwill2022-08-012023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3113535358dpl:GroupUndertakings2022-08-012023-07-3113535358dpl:ParticipatingInterests2022-08-012023-07-3113535358dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-012023-07-3113535358core:ListedExchangeTraded2022-08-012023-07-3113535358dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-012023-07-3113535358core:UnlistedNon-exchangeTraded2022-08-012023-07-3113535358core:NetGoodwill2024-07-3113535358core:IntangibleAssetsOtherThanGoodwill2024-07-3113535358core:LandBuildings2024-07-3113535358core:PlantMachinery2024-07-3113535358core:Vehicles2024-07-3113535358core:FurnitureFittings2024-07-3113535358core:OfficeEquipment2024-07-3113535358core:AfterOneYear2024-07-3113535358core:WithinOneYear2024-07-3113535358core:ListedExchangeTraded2024-07-3113535358core:UnlistedNon-exchangeTraded2024-07-3113535358core:ShareCapital2024-07-3113535358core:SharePremium2024-07-3113535358core:RevaluationReserve2024-07-3113535358core:OtherReservesSubtotal2024-07-3113535358core:RetainedEarningsAccumulatedLosses2024-07-3113535358core:NetGoodwill2023-07-3113535358core:IntangibleAssetsOtherThanGoodwill2023-07-3113535358core:LandBuildings2023-07-3113535358core:PlantMachinery2023-07-3113535358core:Vehicles2023-07-3113535358core:FurnitureFittings2023-07-3113535358core:OfficeEquipment2023-07-3113535358core:AfterOneYear2023-07-3113535358core:WithinOneYear2023-07-3113535358core:ListedExchangeTraded2023-07-3113535358core:UnlistedNon-exchangeTraded2023-07-3113535358core:ShareCapital2023-07-3113535358core:SharePremium2023-07-3113535358core:RevaluationReserve2023-07-3113535358core:OtherReservesSubtotal2023-07-3113535358core:RetainedEarningsAccumulatedLosses2023-07-3113535358core:NetGoodwill2022-08-0113535358core:IntangibleAssetsOtherThanGoodwill2022-08-0113535358core:LandBuildings2022-08-0113535358core:PlantMachinery2022-08-0113535358core:Vehicles2022-08-0113535358core:FurnitureFittings2022-08-0113535358core:OfficeEquipment2022-08-0113535358core:AfterOneYear2022-08-0113535358core:WithinOneYear2022-08-0113535358core:ListedExchangeTraded2022-08-0113535358core:UnlistedNon-exchangeTraded2022-08-0113535358core:ShareCapital2022-08-0113535358core:SharePremium2022-08-0113535358core:RevaluationReserve2022-08-0113535358core:OtherReservesSubtotal2022-08-0113535358core:RetainedEarningsAccumulatedLosses2022-08-0113535358core:AfterOneYear2023-08-012024-07-3113535358core:WithinOneYear2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-012024-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2024-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-07-3113535358core:Non-currentFinancialInstrumentscore:CostValuation2023-07-3113535358core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-3113535358core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-3113535358bus:Director12023-08-012024-07-31

AKOMA THERAPY LTD

Registered Number
13535358
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2024

AKOMA THERAPY LTD
Company Information
for the year from 1 August 2023 to 31 July 2024

Director

Carl Barge

Registered Address

71-75 Shelton Street
Covent Garden
London
WC2H 9JQ

Registered Number

13535358 (England and Wales)
AKOMA THERAPY LTD
Balance Sheet as at
31 July 2024

Notes

2024

2023

£

£

£

£

Current assets
Debtors32,4067,619
Cash at bank and on hand2,6711,982
5,0779,601
Creditors amounts falling due within one year4(4,029)(2,786)
Net current assets (liabilities)1,0486,815
Total assets less current liabilities1,0486,815
Net assets1,0486,815
Capital and reserves
Called up share capital100100
Profit and loss account9486,715
Shareholders' funds1,0486,815
The financial statements were approved and authorised for issue by the Director on 26 March 2025, and are signed on its behalf by:
Carl Barge
Director
Registered Company No. 13535358
AKOMA THERAPY LTD
Notes to the Financial Statements
for the year ended 31 July 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
2.Average number of employees

20242023
Average number of employees during the year00
3.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables2,406221
Other debtors-7,398
Total2,4067,619
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
4.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables1,024213
Taxation and social security3,0052,573
Total4,0292,786
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.